Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant

Raleigh A. Bowden, Monica Cays, Ted Gooley, Richard D. Mamelok, Jo Anne Van Burik

Research output: Contribution to journalArticlepeer-review

101 Scopus citations

Abstract

Amphotericin B colloidal dispersion (ABCD; Amphocil) was evaluated in a phase I dose-escalation study in 75 marrow transplant patients with invasive fungal infections (primarily Aspergillus or Candida species) to determine the toxicity profile, maximum tolerated dose, and clinical response. Escalating doses of 0.5-8.0 mg/kg in 0.5-mg/kg/patient increments were given up to 6 weeks. No infusion-related toxicities were observed in 32% of the patients; 52% had grade 2 and 5% had grade 3 toxicity. No appreciable renal toxicity was observed at any dose level. The estimated maximum tolerated dose was 7.5 mg/kg, defined by rigors and chills and hypotension in 3 of 5 patients at 8.0 mg/kg. The complete or partial response rate across dose levels and infection types was 52%. For specific types of infections, 53% of patients with fungemia had complete responses, and 52% of patients with pneumonia had complete or partial responses. ABCD was safe at doses to 7.5 mg/kg and had tolerable infusion-related toxicity and demonstrate antifungal activity.

Original languageEnglish (US)
Pages (from-to)1208-1215
Number of pages8
JournalJournal of Infectious Diseases
Volume173
Issue number5
DOIs
StatePublished - 1996

Bibliographical note

Funding Information:
Received 19 April 1995; revised 13 December 1995. All patients gave informed consent according to the guidelines of the Fred Hutchinson Cancer Research Center Institutional Review Board. Grant support: National Institutes of Health (CA-18029, CA-15704, and HL-3644); Sequus Pharmaceuticals, Reprints or correspondence: Dr. Raleigh A. Bowden, Infectious Diseases, Box 358080, Fred Hutchinson Cancer Research Center, 1124 Columbia St., Seattle, WA 98104-2092.

Fingerprint Dive into the research topics of 'Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant'. Together they form a unique fingerprint.

Cite this